HomeNews

News

Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Most cancers

An knowledgeable discusses the FDA approval of Enhertu in unresectable or metastatic HR+, HER2-low or -ultralow breast most cancers: © inventory.adobe.comOn Jan. 27,...

Navigating Time and Feelings After Testicular Most cancers

Brian Sluga is now a testicular most cancers survivor after receiving the prognosis when he was 20 years previous. Make amends for Brian's blogs...

FDA Approves Opdivo Qvantig – NCI

February 19, 2025, ...

What Sufferers With Most cancers Must Know About Counterfeit Medicine Threat

Sufferers with most cancers face dangers from counterfeit medication offered on-line, and will confirm pharmacy accreditation and search monetary help.The overwhelming majority of...

SBRT Could Be Superior to Radiofrequency Ablation in Liver Most cancers

SBRT improved native progression-free survival over RFA in small recurrent HCC, significantly in tumors 2 cm or much less, with comparable PFS, OS...

Hot Topics